Dynamics of TNF-α and INF-γ content in blood serum in connection with the marker profile of patients with acute hepatitis B at different degrees of severity of the disease





hepatitis B, cytokines


The aim – is to analyze the dynamics of the content of TNF-α and INF-γ in the serum in connection with the marker profile of patients with acute hepatitis B at different degrees of severity of the disease.

Materials and methods. 32 patients with AHB were examined in the dynamics of the disease with the determination of HBsAg, HBeAg, anti-HBs and anti-HBe, the content of TNF-α and IFN-γ by ELISA. Statistical processing was performed in Statistica 13 for Windows (StatSoft Inc., No. JPZ804I382130ARCN10-J).

Results. Patients with severe (40.6 %) and moderate (37.5 %) courses of the disease predominate among patients with AHB. Severe course of AHB, compared with the moderate course, was characterized by higher levels of hyperbilirubinemia (P < 0.05), cytolytic syndrome (P < 0.05), hypoproteinemia (P < 0.05), and signs of hypocoagulation (P < 0.05). HBsAg (P < 0.05) was more often observed in patients with moderate and severe AHB (P < 0.05) in the absence of a difference in the frequency of seroconversion for HBeAg. Seroconversion of HBsAg/anti-HBs at 6 months was lowest after mild (66.7 %), compared with moderate (91.7 %) and severe (100.0 %) (P > 0.05) course of the disease. Regardless of the severity of AHB, the content of TNF-α was higher (P < 0.05) than in healthy individuals and highest in the severe course of the disease (P < 0.05). The content of INF-γ was higher than in healthy individuals (P < 0.05), regardless of the severity of the disease. TNF-α correlated with the severity of AHB (r = 0.57, P < 0.05), the level of total bilirubin (r = 0.65, P < 0.05), INR (r = 0.42, P < 0.05) and PI (r = -0.48, P < 0.05) at hospitalization.

Conclusions. Patients with severe (40.6 %) and moderate (37.5 %) courses of the disease predominate among the hospitalized patients with AHB. At hospitalization, the content of TNF-α is highest in the severe course of the disease (P < 0.05). The content of INF-γ is higher than in healthy individuals (P < 0.05), regardless of the severity of the course of AHB. At hospitalization, all patients were positive for HBsAg and IgM anti-HBcorAg, the vast majority of patients for HBeAg. Positive HBsAg was more often (P < 0.05) in patients with a moderate course of AHB during discharge from the hospital. HBeAg was preserved in 28.6 % of patients with the mild course. Chronic HBV infection was observed in 3.6 % of patients with the mild course.

Author Biography

A. B. Khelemendyk, Zaporizhzhia State Medical University, Ukraine

Assistant of the Department of Infectious Diseases


World Health Organization. (2021). Global progress report on HIV, viral hepatitis and sexually transmitted infections. https://www.who.int/publications/i/item/9789240027077externalicon

Trépo, C., Chan, H. L., & Lok, A. (2014). Hepatitis B virus infection. Lancet, 384(9959), 2053-2063. https://doi.org/10.1016/S0140-6736(14)60220-8

Zoulim, F., & Durantel, D. (2015). Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harbor perspectives in medicine, 5(4), a021501. https://doi.org/10.1101/cshperspect.a021501

World Health Organization. (2020, December 21). Hepatitis B. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b

Shah, N. J., Aloysius, M. M., Sharma, N. R., & Pallav, K. (2021). Advances in treatment and prevention of hepatitis B. World journal of gastrointestinal pharmacology and therapeutics, 12(4), 56-78. https://doi.org/10.4292/wjgpt.v12.i4.56

Polaris Observatory Collaborators (2018). Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The lancet. Gastroenterology & hepatology, 3(6), 383-403. https://doi.org/10.1016/S2468-1253(18)30056-6

Dunn, C., Peppa, D., Khanna, P., Nebbia, G., Jones, M., Brendish, N., Lascar, R. M., Brown, D., Gilson, R. J., Tedder, R. J., Dusheiko, G. M., Jacobs, M., Klenerman, P., & Maini, M. K. (2009). Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology, 137(4), 1289-1300. https://doi.org/10.1053/j.gastro.2009.06.054

Engle, R. E., De Battista, D., Danoff, E. J., Nguyen, H., Chen, Z., Lusso, P., Purcell, R. H., & Farci, P. (2020). Distinct Cytokine Profiles Correlate with Disease Severity and Outcome in Longitudinal Studies of Acute Hepatitis B Virus and Hepatitis D Virus Infection in Chimpanzees. mBio, 11(6), e02580-20. https://doi.org/10.1128/mBio.02580-20

Kimura, K., Kakimi, K., Wieland, S., Guidotti, L. G., & Chisari, F. V. (2002). Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. Journal of immunology, 169(9), 5188-5195. https://doi.org/10.4049/jimmunol.169.9.5188

Liu, F., Duan, X., Wan, Z., Zang, H., You, S., Yang, R., Liu, H., Li, D., Li, J., Zhang, Y., & Xin, S. (2016). Lower number and decreased function of natural killer cells in hepatitis B virus related acute-on-chronic liver failure. Clinics and research in hepatology and gastroenterology, 40(5), 605-613. https://doi.org/10.1016/j.clinre.2016.01.004

Khelemendyk, A. B., Riabokon, O. V., Riabokon, Yu. Yu., & Kalashnyk, K. V. (2021). Relationships between HBeAg status of patients with chronic hepatitis B and changes in serum TNF-α, viral load and severity of morphological changes in the liver according to non-invasive tests. Pathologia, 18(1), 80-85. https://doi.org/10.14739/2310-1237.2021.1.228933

Fisicaro, P., Valdatta, C., Boni, C., Massari, M., Mori, C., Zerbini, A., Orlandini, A., Sacchelli, L., Missale, G., & Ferrari, C. (2009). Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut, 58(7), 974-982. https://doi.org/10.1136/gut.2008.163600

Guidotti, L. G., Ishikawa, T., Hobbs, M. V., Matzke, B., Schreiber, R., & Chisari, F. V. (1996). Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity, 4(1), 25-36. https://doi.org/10.1016/s1074-7613(00)80295-2

Xia, Y., Stadler, D., Lucifora, J., Reisinger, F., Webb, D., Hösel, M., Michler, T., Wisskirchen, K., Cheng, X., Zhang, K., Chou, W. M., Wettengel, J. M., Malo, A., Bohne, F., Hoffmann, D., Eyer, F., Thimme, R., Falk, C. S., Thasler, W. E., Heikenwalder, M., … Protzer, U. (2016). Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis. Gastroenterology, 150(1), 194-205. https://doi.org/10.1053/j.gastro.2015.09.026

Campos-Valdez, M., Monroy-Ramírez, H. C., Armendáriz-Borunda, J., & Sánchez-Orozco, L. V. (2021). Molecular Mechanisms during Hepatitis B Infection and the Effects of the Virus Variability. Viruses, 13(6), 1167. https://doi.org/10.3390/v13061167

Tseng, T. C., & Huang, L. R. (2017). Immunopathogenesis of Hepatitis B Virus. Journal of Infectious Diseases, 216, 765-770. https://doi.org/10.1093/infdis/jix356

Roth, R. A., Maiuri, A. R., & Ganey, P. E. (2017). Idiosyncratic Drug-Induced Liver Injury: Is Drug-Cytokine Interaction the Linchpin?. The Journal of pharmacology and experimental therapeutics, 360(2), 461-470. https://doi.org/10.1124/jpet.116.237578

Wullaert, A., van Loo, G., Heyninck, K., & Beyaert, R. (2007). Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocrine reviews, 28(4), 365-386. https://doi.org/10.1210/er.2006-0031

Sandhu, P., Haque, M., Humphries-Bickley, T., Ravi, S., & Song, J. (2017). Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies. Frontiers in immunology, 8, 436. https://doi.org/10.3389/fimmu.2017.00436

World Gastroenterology Organisation. (2015). Global Guideline Hepatitis B. https://www.worldgastroenterology.org/UserFiles/file/guidelines/hepatitis-b-russian-2015.pdf

Luangsay, S., Gruffaz, M., Isorce, N., Testoni, B., Michelet, M., Faure-Dupuy, S., Maadadi, S., Ait-Goughoulte, M., Parent, R., Rivoire, M., Javanbakht, H., Lucifora, J., Durantel, D., & Zoulim, F. (2015). Early inhibition of hepatocyte innate responses by hepatitis B virus. Journal of hepatology, 63(6), 1314-1322. https://doi.org/10.1016/j.jhep.2015.07.014

Stacey, A. R., Norris, P. J., Qin, L., Haygreen, E. A., Taylor, E., Heitman, J., Lebedeva, M., DeCamp, A., Li, D., Grove, D., Self, S. G., & Borrow, P. (2009). Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. Journal of virology, 83(8), 3719-3733. https://doi.org/10.1128/JVI.01844-08

Yoshio, S., Mano, Y., Doi, H., Shoji, H., Shimagaki, T., Sakamoto, Y., Kawai, H., Matsuda, M., Mori, T., Osawa, Y., Korenaga, M., Sugiyama, M., Mizokami, M., Mita, E., Katayama, K., Tanaka, J., & Kanto, T. (2018). Cytokine and chemokine signatures associated with hepatitis B surface antigen loss in hepatitis B patients. JCI insight, 3(20), e122268. https://doi.org/10.1172/jci.insight.122268

Lucifora, J., Xia, Y., Reisinger, F., Zhang, K., Stadler, D., Cheng, X., Sprinzl, M. F., Koppensteiner, H., Makowska, Z., Volz, T., Remouchamps, C., Chou, W. M., Thasler, W. E., Hüser, N., Durantel, D., Liang, T. J., Münk, C., Heim, M. H., Browning, J. L., Dejardin, E., … Protzer, U. (2014). Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science, 343(6176), 1221-1228. https://doi.org/10.1126/science.1243462

Zhao, S., Jiang, J., Jing, Y., Liu, W., Yang, X., Hou, X., Gao, L., & Wei, L. (2020). The concentration of tumor necrosis factor-α determines its protective or damaging effect on liver injury by regulating Yap activity. Cell death & disease, 11(1), 70. https://doi.org/10.1038/s41419-020-2264-z

Lopetuso, L. R., Mocci, G., Marzo, M., D'Aversa, F., Rapaccini, G. L., Guidi, L., Armuzzi, A., Gasbarrini, A., & Papa, A. (2018). Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver. International journal of molecular sciences, 19(8), 2199. https://doi.org/10.3390/ijms19082199

Guidotti, L. G., & Chisari, F. V. (2001). Noncytolytic control of viral infections by the innate and adaptive immune response. Annual review of immunology, 19, 65-91. https://doi.org/10.1146/annurev.immunol.19.1.65

Tzeng, H. T., Tsai, H. F., Chyuan, I. T., Liao, H. J., Chen, C. J., Chen, P. J., & Hsu, P. N. (2014). Tumor necrosis factor-alpha induced by hepatitis B virus core mediating the immune response for hepatitis B viral clearance in mice model. PloS one, 9(7), e103008. https://doi.org/10.1371/journal.pone.0103008



How to Cite

Khelemendyk AB. Dynamics of TNF-α and INF-γ content in blood serum in connection with the marker profile of patients with acute hepatitis B at different degrees of severity of the disease. Current issues in pharmacy and medicine: science and practice [Internet]. 2022Feb.15 [cited 2024Jun.21];15(1):59-66. Available from: http://pharmed.zsmu.edu.ua/article/view/251211



Original research